CIA
FBLG icon

Concurrent Investment Advisors’s FibroBiologics FBLG Stock Holding History

Concurrent Investment Advisors’s Portfolio FBLG Stock Details FBLG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-1,764
Closed -$7.93K – 2064
2025
Q4 		$7.93K Hold
1,764
– – ﹤0.01% 1768
2025
Q3 		$19.3K Hold
1,764
– – ﹤0.01% 1471
2025
Q2 		$22K Hold
1,764
– – ﹤0.01% 1376
2025
Q1 		$31.8K Hold
1,764
– – ﹤0.01% 1208
2024
Q4 		$70.6K Hold
1,764
– – ﹤0.01% 1056
2024
Q3 		$109K Hold
1,764
– – ﹤0.01% 999
2024
Q2 		$176K Buy
+1,764
New +$336K 0.01% 891

Other funds holding FBLG

Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
FEG
Fund Evaluation Group Cincinnati, Ohio $3.7B AUM 16.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CFP
Cascade Financial Partners San Diego, California $1.15B AUM 33.6% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
NA
NewEdge Advisors New Orleans, Louisiana $33.6B AUM 31.03% 1-Year Est. Return
Vanguard Global Advisers
Vanguard Global Advisers Malvern, Pennsylvania $215B AUM

Concurrent Investment Advisors's FBLG Position: Q1 2026 in Review

Concurrent Investment Advisors sold out of FibroBiologics (FBLG) in Q1 2026, closing a stake of 1,764 shares — an estimated $7.93K sold.

Concurrent Investment Advisors first reported a position in FBLG in Q2 2024 and held it in 7 quarters. The position peaked at $176K in Q2 2024. 17 funds tracked by Wall St. Rank hold FBLG as of Q1 2026.

  • Concurrent Investment Advisors reported no remaining FibroBiologics position as of Q1 2026 after selling out during the quarter.
  • Concurrent Investment Advisors sold 1,764 FibroBiologics shares in Q1 2026, an estimated $7.93K.
  • Concurrent Investment Advisors first reported a position in FibroBiologics in Q2 2024 and held it in 7 quarters.
  • Concurrent Investment Advisors's FibroBiologics position peaked at $176K in Q2 2024.
  • 17 funds tracked by Wall St. Rank held FibroBiologics as of Q1 2026.

Based on Concurrent Investment Advisors's 13F filing for Q1 2026, filed 21 Apr 2026.